Key Players are Abbott Laboratories (U.S.), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S
(PRWEB) March 20, 2015
The blood screening market is a growing field that has witnessed a number of technological advancements since its inception,such as a shift from first-generation ELISA to advanced NAT technologies.
The global blood screening market is expected to reach $2.5 billion by 2019 from $1.55 billion in 2014 growing at a CAGR of 10.4% from 2014 to 2019.
Key players are focusing on incorporating advanced and innovative features in their products to increase their respective shares in the market. With this view, companies are focusing on new product launches, agreements, expansions and acquisitions to attain a leadership position in the market.
Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=267747042
The report segments the blood screening market on the basis of products and services, technologies, end users and regions. Among various products the reagents segment accounted for the largest share of the blood screening market in 2014. This segment is also expected to grow at the highest CAGR during the forecast period owing to the increasing adoption rate of NAT, rising number of blood donations and growing demand of blood for transfusion.
Based on regions, the global blood screening market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). In 2014 North America accounted for the largest share of the market while Asia witnessed the highest growth rate.